Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer

NCT04186819 is registered in ClinicalTrials.gov with Blue Earth Diagnostics as lead sponsor.

NCT NCT04186819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04186819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer
Lead sponsor
Blue Earth Diagnostics
Phase
Phase 3
Overall status
Completed
Start date
March 2, 2020
Completion date
June 21, 2021
Enrollment
356 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer